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Determination of the major serogroups is an important step for establishing a vaccine programme and 
management strategy targeting Neisseria meningitidis. From April 2010 to November 2016, a total 
of 25 N. meningitidis isolates were collected in South Korea, in collaboration with the Korean Society 
of Clinical Microbiology. Among isolates, 19 isolates were recovered from blood and/or cerebrospinal 
fluid (CSF) in 46 patients who suffered from invasive meningococcal disease (IMD), and six isolates were 
found in sputum or the throat. The most common serogroup was serogroup B (overall, 36%, n = 9/25; 
IMD, 37%, n = 7/19), which was isolated in every year of the research period except for 2011. There 
were five serogroup W isolates recovered from patients in military service. W was no longer isolated 
after initiation of a vaccine programme for military trainees, but serogroup B caused meningitis in an 
army recruit training centre in 2015. In MLST analysis, 14 sequence types were found, and all isolates 
belonging to W showed the same molecular epidemiologic characteristics (W:P1.5-1, 2-2:F3-9:ST-8912). 
All isolates showed susceptibility to ceftriaxone, meropenem, ciprofloxacin, minocycline, and rifampin; 
however, the susceptibility rates to penicillin and ampicillin for isolates with W and C capsules were 22% 
and 30%, respectively.
Neisseria meningitidis isolates can cause asymptomatic colonization or severe invasive infections. Invasive menin-
gococcal disease (IMD) may develop as acute sepsis or meningitis1, and meningococcal meningitis combined with 
septic shock is responsible for a higher mortality (adjusted odds ratio, 23.3) than simple meningitis2. Although 
infants and children are the main targets of N. meningitidis infection, outbreaks in adolescents and young adults 
can occur as well. The prevalence is diverse in different countries, ranging from 0.16-1.65 cases/100,000 indi-
viduals in well-developed countries to over 300 cases/100,000 individuals in the sub-Saharan meningitis belt1,3. 
According to global disability-adjusted life years (DALY) estimation, the burdens of total bacterial and meningo-
coccal meningitis were 21,014.9 and 4,314.7 (20.5% of the total bacterial meningitis burden) in 2013, repectively4.
The clinical manifestations of meningococcal meningitis can vary and include headache and neck stiffness; 
some patients may be misdiagnosed at early stages due to vague symptoms. Meningitis combined with meningo-
coccal septic shock can result in death in approximately 30% of patients, with an increasing death rate associated 
with age (adjusted odds ratio of 1.02 per 1-year increase in age)5. Rapid progression and high mortality can make 
it difficult to properly manage patients in certain circumstances, although vaccines have been developed to over-
come this serious infection. The most important virulence factor causing invasive infection is the polysaccharide 
capsule, and this structure is the main target of vaccines. Currently, 12 different serogroups of N. meningitidis can 
be distinguished5,6. Determination of the major serogroups is important in establishing a vaccine programme and 
management strategy because the distribution of prevalent serogroups may be diverse based on the country and 
other factors. On the other hand, an IMD outbreak can also occur among young adults who reside in dormito-
ries. Because of the high mortality and morbidity of invasive meningococcal infections, appropriate molecular 
epidemiologic analysis is required to manage and control dissemination. The recent emergence of antimicrobial 
resistance to penicillin has become another problem for managing and treating N. meningitidis infections7. In this 
study, we aimed to investigate the sero/genogroups, PorA subtypes, FetA subtypes, multilocus sequence types 
(MLSTs), and antimicrobial susceptibility of N. meningitidis using isolates collected across South Korea.
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Results
From April 2010 to November 2016, a total of 46 IMD patients who could represent all cases of IMD in Korea 
were reported to the Korea Centers for Disease Control and Prevention (CDC), and 19 isolates were recovered 
from blood and/or cerebrospinal fluid (CSF) among 46 IMD patients. Four isolates were recovered from the 
sputum of patients who were admitted under suspicion of pneumonia, and two isolates that could be regarded as 
normal colonizers were incidentally recovered from the throat. All isolates were collected from 16 laboratories, 
which were located distantly in South Korea, and the number of isolates ranged broadly from two to five isolates 
per year (Fig. 1). The ages of the patients from whom N. meningitidis were isolated ranged broadly from 1 to 76 
years; although the ages of IMD patients ranged from 1 to 64 years, the age range for those who worked in mili-
tary service was limited to 20 and 21 years.
Among the 19 isolates recovered from blood or CSF, the most common serogroup was serogroup B (7/19, 
37%). All five isolates belonging to serogroup W were recovered from the blood or CSF of IMD patients who 
were involved in military service. Although serogroup W was no longer isolated after initiation of a vaccine 
programme (MenACWY-CRM, Menveo, GlaxoSmithKline) for military trainees, serogroup B caused meningitis 
at an army recruit training centre in 2015, two years after vaccination was introduced in 2013. Serogroup C was 
only found in IMD patients, similar to serogroup W. Serogroup E and the non-typeable serogroup were found 
since 2013. The six isolates recovered from sputum or the throat showed diverse serogroups: B, two isolates; Y, two 
isolates; E, one isolate; and non-typeable, one isolate.
In MLST analysis, 14 sequence types were found (Table 1), and 11 types were associated with IMD. Among 
the seven isolates belonging to serogroup B recovered from IMD patients, three isolates showed ST-3091 con-
sistent with clonal complex (cc) 269, but the combinations of the FetA type and PorA types were different from 
each other: B:P1.20, 23-2:F3-6:ST-3091(cc269); B:P1.19, 15:F3-68:ST-3091(cc269); and B:P1.19-2, 15:F3-6:ST-
3091(cc269). Other serogroup B isolates recovered from blood and/or CSF belonged to cc35 (1), cc41/44 (1), cc60 
(1), and cc162 (1). The two serogroup B isolates found in sputum and the throat belonged to cc41/44 (B:P1.22, 
15:F3-6:ST-2136) and cc269 (B:P1.19, 15:F3-6:ST3091). All isolates belonging to W showed the same molecu-
lar epidemiologic characteristics (W:P1.5-1, 2-2:F3-9:ST-8912). ST-8912 was a very independent sequence type 
that was not assigned to any clonal complex in eBurst analysis. The four isolates in serogroup C belonged to two 
clonal complexes (cc11, cc32). Three isolates showed the same FetA type and PorA types and differed in two loci: 
C:P1.22, 14-6:F1-7:ST-11278(cc32) and C:P1.22, 14-6:F1-7:ST-12771(cc32).
The three serogroup E isolates found in IMD patients showed different clonal complexes, E:P1.19, 15:F5-5:ST-
178(cc178), E:P1.7-2, 2-2:F1-7:ST-44(cc41/44), and E:P1.5-1, 10-1:F4-1:ST-1655(cc23), and the one isolate 
from sputum showed the same sequence type and PorA type as one blood isolate but a different FetA type 
(E:P1.19, 15:F5-28:ST-178(cc178)). Serogroup Y was only found in sputum and throat isolates, and both iso-
lates showed the same PorA type but different sequence and FetA types (Y:P1.5-1, 2-2:F4-1:ST-12770, Y:P1.5-1, 
2-2:F5-8:ST-12768). The serogroup of one isolate belonging to ST-44 could not be determined by two molecular 
methods and latex agglutination.
The antimicrobial susceptibility determined by Etest is summarized in Table 2. All of the isolates showed 100% 
susceptibility to ceftriaxone, meropenem, ciprofloxacin, minocycline and rifampin. Ceftriaxone and meropenem 
showed MIC ranges of ≤0.002–0.004 µg/mL and 0.002–0.064 µg/mL, respectively. Overall the MIC50 and MIC90 
of ceftriaxone were ≤0.002 µg/mL and 0.003 µg/mL, and those of meropenem were 0.023 µg/mL and 0.047 µg/mL, 
respectively. The rates of isolates susceptible to penicillin and ampicillin were 20% and 32%, and the MIC ranges 
were 0.006–0.38 µg/mL and 0.016–0.75 µg/mL, respectively. Five isolates (20%) showed penicillin MIC of values 
of 0.38 µg/mL, which was higher than the intermediate breakpoints, and four of them belonged to serogroup W, 
Figure 1. Summary of the number of isolates collected and their serogroups from 2010 to 2016 in South Korea 
according to patient type. Each letter designates the serogroups for each isolate: B, serogroup B; C, serogroup 
C; W, serogroup W; Y, serogroup Y; E, serogroup E; N, non-typeable serogroup. The green colour indicates a 
carrier (throat).
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while one was in serogroup C (Fig. 2). Isolates belonging to serogroup W also showed high MIC values against 
ampicillin (MIC range 0.5–0.75 µg/mL, intermediate).
Discussion
The prevalence of IMD may vary widely in different regions and countries. In the United States, the CDC reported 
that the prevalence of meningitis and bacteremia due to N. meningitidis was 0.16 cases/100,000 individuals; in 
2015, 12.5% of these infected patients died (the mortality of meningitis was 9.1% and of sepsis 20%)3. In Europe, 
the mean prevalence of IMD was found to be 0.5 cases/100,000 individuals (range 0.2–3.1 cases/100,000) in 2014 
by the European CDC8. In South Korea, all cases of IMD must be reported to the Korean CDC by law for infec-
tious disease prevention and control, and the prevalence of meningococcal meningitis in the country was recently 
shown to be very low since 2010. A total of 46 cases of meningococcal infection confirmed by culture, serologic 
methods, or molecular tests were reported from 2010 to 2016 (6.57 cases per year)9, and these cases also represent 
the total IMD cases in South Korea during the course of this study. The recovery rate of culturable N. meningitidis 
from patients who are suspected to have IMD is generally low in other reports10. According to Bronska et al., only 
35% of CSF and 39% of blood samples were culture positive among 37 patients with laboratory-confirmed IMD. 
In another study in England, which evaluated the value of PCR testing for IMD, the positive rate of culture was 
42.9% among 1,924 IMD cases confirmed by PCR and culture11. In this study, we collected 19 isolates recovered 
Diagnosis Year Sex Age Specimen Military service Serogroups Clonal complex Sequence type FetA PorA VR1 PorA VR2
IMD 2010 M 14 Blood B ST-35 complex 35 F4-1 22-1 14
IMD 2010 F 6 Blood B ST-60 complex 3014 F1-7 5 2
IMD 2010 M 14 Blood B ST-269 complex 3091 F3-6 20 23-2
IMD 2013 F 64 CSF B ST-269 complex 3091 F3-68 19 15
IMD 2014 M 1 CSF B ST-269 complex 3091 F3-6 19-2 15
IMD 2015 M 20 CSF O B ST-41/44 complex/Lineage 3 44 F4-27 12-1 1
IMD 2016 F 44 Blood B ST-162 complex 162 F5-9 20 NA
IMD 2013 F 22 Blood C ST-11 complex/ET-37 complex 11 F3-6 5-1 10-8
IMD 2013 F 39 CSF C ST-32 complex/ET-5 complex 12771 F1-7 22 14-6
IMD 2015 M 20 Blood C ST-32 complex/ET-5 complex 11278 F1-7 22 14-6
IMD 2016 M 20 Blood C ST-32 complex/ET-5 complex 11278 F1-7 22 14-6
IMD 2011 M 20 CSF O W NA 8912 F3-9 5-1 2-2
IMD 2011 M 20 Blood O W NA 8912 F3-9 5-1 2-2
IMD 2012 M 21 CSF O W NA 8912 F3-9 5-1 2-2
IMD 2012 M 20 CSF O W NA 8912 F3-9 5-1 2-2
IMD 2012 M 20 Blood O W NA 8912 F3-9 5-1 2-2
IMD 2014 F 54 Blood E ST-178 complex 178 F5-5 19 15
IMD 2015 M 16 CSF E ST-41/44 complex/Lineage 3 44 F1-7 7-2 2-2
IMD 2015 M 20 CSF E ST-23 complex/Cluster A3 1655 F4-1 5-1 10-1
Pneumonia 2012 M 69 Sputum B ST-41/44 complex/Lineage 3 2136 F3-6 22 14
Pneumonia 2012 F 37 Sputum Y NA 12770 F4-1 5-1 2-2
Pneumonia 2014 F 76 Sputum E ST-178 complex 178 F5-28 19 15
Pneumonia 2013 M 51 Sputum NT ST-41/44 complex/Lineage 3 44 F1-7 NA 13-2
Carrier 2010 M 46 Throat Y NA 12768 F5-8 5-1 2-2
Carrier 2016 M 27 Throat B ST-269 complex 3091 F3-6 19 15
Table 1. Summary of epidemiologic data of N. meningitidis isolated in South Korea from 2010 to 2016. 
*Abbreviations: MLST, multilocus sequence typing; CC, clonal complex; NA, not available; URI, upper 
respiratory infection.
Antibiotics
Distribution of MIC (µg/mL) Antimicrobial susceptibility (%)
Range MIC50 MIC90 Susceptible Intermediate Resistant
Penicillin 0.006–0.38 0.125 0.38 22 56 22
Ampicillin 0.016–0.75 0.25 0.75 30 70 0
Ceftriaxone ≤0.002–0.004 ≤0.002 0.003 100 0 0
Meropenem 0.002–0.064 0.023 0.047 100 0 0
Ciprofloxacin 0.002–0.006 0.003 0.004 100 0 0
Minocycline 0.047–0.38 0.19 0.25 100 0 0
Rifampin 0.003–0.125 0.012 0.023 100 0 0
Table 2. Antimicrobial susceptibility of N. meningitidis isolated in South Korea from 2010 to 2016 (n = 25).
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from blood or CSF and six isolates from sputum and the throat. The number of isolates (19/46, 41.3%) collected 
was adequate when the low recovery rate of culture is considered. Although the prevalence of IMD was very low 
in South Korea, IMD also occurred, and a small outbreak of serogroup Y belonging to cc23 (P1.5-1, 2-2) was 
reported during 2002 and 200312. In addition, Kim et al. reported that 13.2% (n = 92/608) of CSF specimens 
collected in 1999 and 2001 were positive for N. meningitidis, and it was the most prevalent pathogen in pro-
spective population-based surveillance for invasive bacterial meningitis performed in children aged <5 years13. 
Furthermore, the high seroprevalence in the South Korean population between 11 and 55 years of age suggests the 
possibility of an underestimation of the IMD burdens in South Korea14,15. Such an underestimation may occur for 
several reasons, such as a high antibiotics prescription rate in South Korea, difficulties in sampling and testing at 
primary clinics, and the fastidious nature of N. meningitidis. Therefore, surveillance for meningococcal disease to 
determine its epidemiologic characteristics should be performed.
Determination of the serogroup of epidemic N. meningitidis isolates causing invasive infections is very impor-
tant to establish a vaccine programme for public health. Vaccines currently available around the world include 
those based on polysaccharides, polysaccharide conjugates, recombinant protein, and outer membrane vesicles. 
Among them, quadrivalent conjugated meningococcal vaccines for serogroups A, C, Y and W are widely inocu-
lated in many countries. Serogroup B vaccines have been introduced in infants in the UK National immunization 
programme in 2015, in Ireland and in regional programmes in Italy16,17. These vaccines have also been used for 
outbreak control in the Saguenay Lac-Saint-Jean region in Canada as well for other outbreak control in US uni-
versities and elsewhere18.
Among the 71 cases of meningitis and sepsis caused by N. meningitidis in the United States in 2015, 44 cases 
were tested to determine the serogroups, and serogroup B (41%) was the most prevalent2. In Europe, serogroup B 
was also the most dominant and mainly prevalent in infants but decreased in prevalence with age8. Since national 
immunization programmes with MenC conjugate vaccines were introduced in the UK in 1999 and then pro-
gressively across Europe, IMD due to serogroup C decreased in this region19. In contrast to developed countries, 
serogroup A was the most common serogroup in the meningitis belt of the sub-Saharan region19,20; however, it 
became rare due to the introduction of MenAfrivac, while outbreaks caused by serogroups C, W, and X were 
also reported sporadically21,22. According to a previous report23, serogroups X and Y were the most prevalent in 
CSF samples of paediatric meningitis patients from 1999 to 2002 in South Korea. However, the most prevalent 
serogroup became serogroup B from 2010 to 2016, which was isolated every year except for 2011 in our study. 
In molecular epidemiologic analysis, cc269 seemed to be the main clonal complex among serogroup B. It was 
reported that serogroup B (cc32, cc41/44, and cc269) included the endemic strains responsible for sporadic infec-
tions across Europe24 and was regarded as an emerging clone in Canada and the United States25,26. Serogroup B 
bearing P1.19,15, which may belong to cc269, was also found among freshman in a university dormitory in South 
Korea27.
It was surprising that a small outbreak of W occurred in 2011 and 2012 in a military training camp in South 
Korea. It has been suspected that the W outbreak occurred because all of these isolates share the same MLST, FetA 
type and PorA types (W:P1.5-1, 2-2:F3-9:ST-8912), although the isolated regions were very dispersed around 
the nation (Seoul 1, Gyeonggi 1, Busan 1, and Daejeon 2). ST-8912 showed a very independent relationship with 
Figure 2. Distributions of MIC values against penicillin and ampicillin according to serogroup (shaded 
areas indicate intermediate and resistant ranges). Abbreviations: AMP, ampicillin; NS, non-susceptible; PEN, 
penicillin.
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the major clonal complex in eBurst analysis. It is not clear why W:P1.5-1, 2-2:F3-9:ST-8912 caused an outbreak 
among military trainees and from where this clone evolved, so further study is required. It is well known that 
new military trainees can be highly susceptible to IMD, so meningococcal vaccination is recommended for this 
group. However, meningococcal vaccines were not introduced until late 2012 in South Korea, and no additional 
W infections were identified after initiation of a meningococcal vaccine programme. However, serogroup W 
belonging to P1.5-1, 2-2 (ST not available) was also reported among freshmen in a university dormitory, and the 
possibility of an outbreak of the W clone remains27. In some cases, introduction of a vaccine can be associated 
with shifting of the serotype or serogroup and emergence of new serogroups. Differences in the serogroup dis-
tribution are also found in European countries28. The emergence of hypervirulent serogroup C (ST-11) led to the 
introduction of a meningococcal conjugate vaccine programme for serogroup C in Europe29, and the reduced 
proportion of serogroup C caused the proportion of serogroup B to increase8,28. It remains unclear if the emer-
gence of one serogroup B infection belonging to B:P1.12-1, 1:F4-27:ST-44(cc41/44) in military trainees in 2015 
resulted from the serogroup shifting due to vaccination, but serogroup B belonging to cc41/44 could be found in 
healthy South Korean adolescents in 201530. Further surveillance and the introduction of a vaccine for serogroup 
B may be required when the prevalence of serogroup B in both patients and carriers is considered in South Korea. 
It is also possible that the emergence of serogroup E and serogroup non-typeable isolates may be associated with 
the partial application of a vaccine programme, even though serogroup E and non-groupable isolates tend to be 
common in asymptomatic carriage in healthy adolescents (E 12.2% and non-typeable 30.6)30. In our study, two 
IMD cases caused by serogroup E occurred in cancer patients who were immunocompromised.
Three serogroup C isolates in 2013, 2015, and 2016 share the same FetA and PorA types and belong to the 
same cc32, showing a two-allele difference. This clone was already reported in a study that screened university 
freshmen in 200927. Even though the vaccine programme for military trainees started in late 201231, the quadriva-
lent meningococcal vaccine is still not included in the mandatory vaccine programme for the general population 
and is only part of the programme for military service and high-risk patients in South Korea. It is possible that the 
persistence and dissemination of serogroup C cc32 in years 2013 and 2016 were associated with the absence of a 
National Immunization Program except for the military service; therefore, an expansion of the programme may 
be needed in order to consider serogroup C as the second most commonly carried type in healthy adolescents in 
201530.
The N. meningitidis isolates showed susceptibility to most antibiotics except for penicillin and ampicillin. 
Penicillin is regarded as the primary drug treatment in many countries when meningococcal infection is sus-
pected. However, in our study, 78% and 70% of N. meningitidis isolates showed non-susceptibility to penicillin 
and ampicillin, respectively, and 22% of isolates were resistant to penicillin (MIC 0.38 μg/mL). The isolates that 
showed non-susceptibility to penicillin and ampicillin were W clones. It was reported that modification of pen-
icillin binding protein 2 results in the acquisition of resistance to penicillin, and mosaicism can confer cefixime 
resistance similar to N. gonorrhoeae7,32,33. N. meningitidis isolates with decreased ciprofloxacin susceptibility were 
reported in 201634, but all isolates were susceptible to ciprofloxacin, with the highest MIC being 0.006 µg/mL in 
our study.
In conclusion, the most prevalent serogroup of N. meningitidis isolates in South Korea changed from sero-
group X and Y from 1999 to 2001 to serogroup B from 2010 to 2016, and additional introduction of a vaccine for 
serogroup B may be required. Serogroup W (W:P1.5-1, 2-2:F3-9:ST-8912), which was responsible for the small 
military outbreak, is unique and very independent from major clonal complexes. Antimicrobial susceptibilities to 
ceftriaxone, meropenem and ciprofloxacin remained, but most of the isolates were non-susceptible to penicillin 
and ampicillin. Further surveillance of serogroup changes and antimicrobial resistance is needed to control IMD 
in South Korea.
Methods
From April 2010 to November 2016, a total of 25 N. meningitidis isolates were collected in collaboration with 
the Korean Society of Clinical Microbiology (KSCM). The KSCM is an academic society consisting of clinical 
microbiologists who primarily manage clinical microbiology laboratories in hospitals, commercial laboratories, 
and national institutes in South Korea. All hospitals with members of the KSCM were regularly notified of the 
collection of N. meningitidis isolated from clinical specimens. Isolate collection was promoted by regular e-mail 
notifications from 2010 to 2016. When N. meningitidis was isolated from clinical specimens, it was transferred 
to the Research Institute of Bacterial Resistance at Yonsei University College of Medicine. The collected isolates 
were stored in a deep freezer at −70 °C or below prior to analysis. The study design and protocol were reviewed 
and approved by the Institutional Review Board of Severance Hospital in the Yonsei University health system 
(IRB No. 4-2010-0567).
The collected isolates were identified using a Vitek-2 system (bioMerieux, Marcy-l’Etoile, France) and a 
Microflex LT system (Bruker Daltonics, Bremen, Germany). If needed, 16S rRNA amplification and sequencing 
were performed for identification. The 16S rRNA gene was amplified using primers, as suggested by the Clinical 
and Laboratory Standards Institute35, and sequenced at a commercial laboratory (Macrogen, Seoul, South Korea). 
Data were analysed using either the GenBank database (http://www.ncbi.nlm.nih.gov/genebank/) or EzBioCloud 
service (https://www.ezbiocloud.net/identify). Serogroups were screened with two molecular methods and con-
firmed by slide latex agglutination. Conventional multiplex PCR was carried out for the siaD gene for serogroups 
B, C, W, and Y and the orf-2 of a gene cassette for serogroup A36. Bacterial colonies were suspended in 500 μL 
sterile distilled water for DNA extraction, and the DNA concentration was estimated using a spectrophotometer. 
The DNA amplification process consisted of 35 cycles of denaturation at 92 °C for 40 s, annealing at 55 °C for 30 s, 
and polymerization at 72 °C for 20 s. The size of the amplicon was measured by electrophoresis and compared 
with quality control strains for confirmation of serogroup A (CCUG3269), B (CCUG3270), and C (CCUG3271). 
Amplicons corresponding to serogroups W and Y were sequenced by Sanger methods and analysed. The isolate 
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for which the serogroup could not be determined was tested by another molecular method reported by Bennett et 
al.37. Multiplex PCRs for the ctrA gene, serogroup-specific region (X, E, Z and H), and porA gene were amplified, 
and the product was sequenced for confirmation (Macrogen).
Slide latex agglutination was also performed to confirm the serogroup using BD Difco™ Neisseria menin-
gitidis antisera (Becton Dickinson, Sparks, MD, USA). After scraping and suspending several colonies of pure 
cultured N. meningitidis, one drop of colony suspension and antisera for each serogroup was mixed with each of 
the test cards (serogroups A, B, C, D, E, W, X, Y, and Z). Agglutination was regarded as positive, and the result 
was compared with the result of multiplex PCR serogrouping. Multilocus sequence typing (MLST), ferric entero-
bactin transport protein A (FetA) typing, and variable regions (VR) in Porin A (PorA) typing were performed to 
determine the epidemiologic characteristics in all isolates as described in http://neisseria.org/.
The antimicrobial susceptibility was determined using Etest strips (bioMerieux). The minimum inhibitory 
concentrations of penicillin, ampicillin, ceftriaxone, meropenem, minocycline, ciprofloxacin, and rifampin were 
measured after incubation for 20–24 hours at 35 °C in 5% CO2 with Mueller-Hinton agar with 5% sheep blood, 
and the results were interpreted according to the Clinical Laboratory Standards and Institute (CLSI) guidelines38.
Data availability. The datasets generated and/or analysed during the current study are available from the 
corresponding author upon reasonable request.
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